Joseph D N, Hossain M
J Int Med Res. 1985;13(4):209-13. doi: 10.1177/030006058501300403.
In an open, single centre, general practice study, the short acting benzodiazepine lormetazepam (Loramet) was administered nightly for a period of 7 nights to fifty-eight geriatric insomniacs. All patients took 0.5 mg on the first night but were allowed to increase their dosage to 1.0 mg and 1.5 mg as required. The patients assessed the efficacy and acceptability of lormetazepam with the aid of a diary card completed on each morning of the study. The results showed that 65.5% of the patients reported an improvement in their sleep pattern and 76.9% were taking the 0.5 mg dosage by the last night of the study. Throughout the study there was a progressive increase in the mean duration of sleep and a similar increase in the number of patients awaking refreshed. The effects were significant after the second and third nights, respectively. Three patients withdrew from the study, two due to lack of efficacy and one dropped out following the occurrence of side-effects. It was concluded that the results confirm the efficacy and acceptability of lormetazepam and may suggest 0.5 mg to be a more suitable dosage than 1.0 and 1.5 mg in elderly patients.
在一项开放、单中心的全科医学研究中，每晚给58名老年失眠患者服用短效苯二氮䓬类药物氯美扎酮（Loramet），持续7晚。所有患者在第一晚服用0.5毫克，但可根据需要将剂量增加至1.0毫克和1.5毫克。患者借助研究期间每天早晨填写的日记卡评估氯美扎酮的疗效和可接受性。结果显示，65.5%的患者报告睡眠模式有所改善，到研究的最后一晚，76.9%的患者服用0.5毫克剂量。在整个研究过程中，平均睡眠时间逐渐增加，醒来感觉精神焕发的患者数量也有类似增加。分别在第二晚和第三晚后效果显著。三名患者退出研究，两名因疗效不佳，一名在出现副作用后退出。得出的结论是，结果证实了氯美扎酮的疗效和可接受性，并且可能表明在老年患者中，0.5毫克比1.0毫克和1.5毫克是更合适的剂量。
